{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:31:44Z","timestamp":1788496304173,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>X-linked hypophosphatemic rickets (XLH) is a rare inherited metabolic bone disorder caused by excess fibroblast growth factor 23 (FGF23), leading to hypophosphatemia and rickets. Burosumab, a human monoclonal antibody targeting FGF23, was approved for the treatment of XLH in April 2018. By 2022, the FDA extended its approval to include children as young as six months of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe three infants with XLH who began burosumab therapy before one year of age and were monitored for at least one year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical outcomes, including anthropometric measures, skeletal outcomes (Rickets Severity Score [RSS], mechanical axis deviation [MAD], and neck-shaft angle [NSA]), and laboratory parameters, were assessed in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two patients demonstrated satisfactory linear growth, and one experienced growth faltering, possibly due to sleep-disordered breathing or phosphate imbalance. These patients received higher doses of burosumab than the current guideline recommendations for achieving treatment goals aimed at normalizing phosphate levels. The patient\u2019s phosphate levels improved but did not normalize. Bone pain was not formally assessed, but parents reported improvements in their children\u2019s conditions. Importantly, two patients with assessable mechanical axes demonstrated neutral mechanical axis deviations, indicating improved lower limb alignment and supporting the therapeutic efficacy of burosumab. All three patients had favorable RSS outcomes, and none developed long bone diaphyseal bowing or coxa vara following this early initiation of burosumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case series demonstrated potential benefits of early initiation of burosumab treatment for XLH by showing improvements in growth, phosphate levels, and skeletal outcomes. Burosumab appears well tolerated in infancy, but further research is needed to refine dosing strategies and assess its long-term safety and therapeutic efficacy in young patients with XLH. Meticulous monitoring and individualized care are essential throughout treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain language summary<\/jats:title>\n                    <jats:p>This case series followed three infants with X-linked hypophosphatemic rickets (XLH) who initiated burosumab treatment at 6\u2009months of age, filling a significant knowledge gap in early intervention. Despite requiring higher-than-recommended dosing, burosumab demonstrated favorable outcomes in terms of growth parameters and skeletal development over a minimum one-year follow-up. Two patients maintained normal growth trajectories, whereas one experienced temporary growth faltering, which resolved after adenoidectomy. Importantly, neutral mechanical axis deviation was achieved, indicating effective prevention of lower limb deformities. No significant adverse effects were observed. Despite limitations such as a small sample size and short follow-up, these findings suggest that early burosumab therapy can improve outcomes in infantile XLH patients. Further research is needed to refine dosing protocols and assess long-term safety and efficacy in this young population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04177-2","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:16:06Z","timestamp":1767842166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Burosumab in infants with X-linked hypophosphatemic rickets: a case series"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-733X","authenticated-orcid":false,"given":"Ravit","family":"Regev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-8264","authenticated-orcid":false,"given":"Avivit","family":"Brener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-7426","authenticated-orcid":false,"given":"Nitzan","family":"Dror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Krespi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Rapalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Chorna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6019-4159","authenticated-orcid":false,"given":"Ophir","family":"Borger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adar","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-0574","authenticated-orcid":false,"given":"Yael","family":"Lebenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Zeitlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"4177_CR1","doi-asserted-by":"publisher","unstructured":"Baroncelli GI, Mora S. X-Linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management. Front Endocrinol (Lausanne). 2021, Aug;6(12):688309. https:\/\/doi.org\/10.3389\/fendo.2021.688309. PMID: 34421819; PMCID: PMC8378329.","DOI":"10.3389\/fendo.2021.688309"},{"key":"4177_CR2","doi-asserted-by":"publisher","unstructured":"Ho BB, Bergwitz C. FGF23 signalling and physiology. J Mol Endocrinol. 2021 Feb;66(2):R23\u201332. https:\/\/doi.org\/10.1530\/JME-20-0178. PMID: 33338030; PMCID: PMC8782161.","DOI":"10.1530\/JME-20-0178"},{"key":"4177_CR3","doi-asserted-by":"publisher","unstructured":"Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003 Aug;88(8):3591\u201397. https:\/\/doi.org\/10.1210\/jc.2003-030036. PMID: 12915641.","DOI":"10.1210\/jc.2003-030036"},{"key":"4177_CR4","doi-asserted-by":"publisher","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Hgler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;15;393(10189):2416\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(19)30654-3. Epub 2019 May 16.Erratum in:Lancet. 2019 Jul13; 394(10193):120. 10.1016\/S0140-6736(19)31426-6. PMID: 31104833; PMCID: PMC7179969.","DOI":"10.1016\/S0140-6736(19)30654-3"},{"key":"4177_CR5","doi-asserted-by":"publisher","unstructured":"Haffner D, Emma F, Eastwood DM, Biosse Duplan M, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019, Jul;15(7):435\u201355. https:\/\/doi.org\/10.1038\/s41581-019-0152-5. PMID: 31068690; PMCID: PMC7136170.","DOI":"10.1038\/s41581-019-0152-5"},{"key":"4177_CR6","doi-asserted-by":"publisher","unstructured":"Ward LM, Hogler W, Glorieux FH, Portale AA, Whyte MP, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Sochett E, Muroya K, Tanaka H, Pitukcheewanont P, Gottesman GS, Biggin A, Perwad F, Chen A, Lawrence Merritt Ii J, Imel EA. Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period. JBMR Plus. 2024, Jan, 4;8(1):ziad001. https:\/\/doi.org\/10.1093\/jbmrpl\/ziad001. PMID: 38690124; PMCID: PMC11059996.","DOI":"10.1093\/jbmrpl\/ziad001"},{"key":"4177_CR7","unstructured":"US Food and Drug Administration. Crysvita (burosumab-twza) Marketing Approval."},{"key":"4177_CR8","unstructured":"Ultragenyx Pharmaceutical Inc. Dosing for children | Crysvita HCP. 2024."},{"key":"4177_CR9","volume-title":"Crysvita full prescribing Information","author":"Ultragenyx Pharmaceutical Inc","year":"2024","unstructured":"Ultragenyx Pharmaceutical Inc. Crysvita full prescribing Information. 2024."},{"issue":"1","key":"4177_CR10","doi-asserted-by":"publisher","first-page":"e16204","DOI":"10.2196\/16204","volume":"22","author":"JH Chou","year":"2020","unstructured":"Chou JH, Roumiantsev S, Singh R. PediTools electronic growth chart calculators: applications in clinical care, research, and quality improvement. J Med Internet Res. 2020, Jan, 30;22(1):e16204. https:\/\/doi.org\/10.2196\/16204. PMID: 32012066; PMCID: PMC7058170.","journal-title":"J Med Internet Res"},{"issue":"1","key":"4177_CR11","doi-asserted-by":"publisher","first-page":"e20162034","DOI":"10.1542\/peds.2016-2034","volume":"139","author":"DS Freedman","year":"2017","unstructured":"Freedman DS, Sharma AJ, Hamner HC, Pan L, Panzera A, Smith RB, Blanck HM. Trends in weight-for-length among infants in WIC from 2000 to 2014. Pediatrics. 2017, Jan;139(1):e20162034. https:\/\/doi.org\/10.1542\/peds.2016-2034. Epub 2016 Dec 13. PMID: 27965380; PMCID: PMC5359001.","journal-title":"Pediatrics"},{"key":"4177_CR12","unstructured":"Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11. 2002;(246):1\u2013190. PMID: 12043359."},{"key":"4177_CR13","doi-asserted-by":"publisher","unstructured":"Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2(7929):309\u201310. https:\/\/doi.org\/10.1016\/s0140-6736(75)92736-1. PMID: 51461.","DOI":"10.1016\/s0140-6736(75)92736-1"},{"key":"4177_CR14","doi-asserted-by":"publisher","unstructured":"Payne RB. Renal tubular reabsorption of phosphate (TmP\/GFR): indications and interpretation. Ann Clin Biochem. 1998, Mar;35(Pt 2):201\u201306. https:\/\/doi.org\/10.1177\/000456329803500203. PMID: 9547891.","DOI":"10.1177\/000456329803500203"},{"key":"4177_CR15","doi-asserted-by":"publisher","unstructured":"Thacher TD, Fischer PR, Pettifor JM, Lawson JO, Manaster BJ, Reading JC. Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr. 2000, Jun;46(3):132\u201339. https:\/\/doi.org\/10.1093\/tropej\/46.3.132. PMID: 10893912.","DOI":"10.1093\/tropej\/46.3.132"},{"issue":"3","key":"4177_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0030-5898(20)31927-1","volume":"25","author":"D Paley","year":"1994","unstructured":"Paley D, Herzenberg JE, Tetsworth K, McKie J, Bhave A. Deformity planning for frontal and sagittal plane corrective osteotomies. Orthop Clin N Am. 1994, Jul;25(3):425\u201365. PMID: 8028886.","journal-title":"Orthop Clin N Am"},{"issue":"3","key":"4177_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.52628\/87.3.07","volume":"87","author":"P Van Geel","year":"2021","unstructured":"Van Geel P, Cools W, Laumen A. Evolution of head-shaft angle and neck-shaft angle in childhood. Acta Orthop Belg. 2021, Sep;87(3):435\u201341. PMID: 34808716.","journal-title":"Acta Orthop Belg"},{"key":"4177_CR18","doi-asserted-by":"publisher","unstructured":"Levy-Shraga Y, Levi S, Regev R, Gal S, Brener A, Lebenthal Y, Gillis D, Strich D, Zung A, Cleper R, Borovitz Y, Bello R, Tenenbaum A, Zadik Z, Davidovits M, Zeitlin L, Tiosano D. Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study. Eur J Pediatr. 2023 Nov;182(11):5191\u2013202. https:\/\/doi.org\/10.1007\/s00431-023-05190-y. Epub 2023 Sep 14. PMID: 37707589.","DOI":"10.1007\/s00431-023-05190-y"},{"key":"4177_CR19","doi-asserted-by":"publisher","unstructured":"Kamenick P, Briot K, Munns CF, Lancet LAX-L. 2024, Aug, 31;404(10455):887\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(24)01305-9. Epub 2024 Aug 21. PMID: 39181153.","DOI":"10.1016\/S0140-6736(24)01305-9"},{"issue":"5","key":"4177_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/archdischild-2022-324962","volume":"108","author":"EYX Walker","year":"2023","unstructured":"Walker EYX, Lindsay TAJ, Allgrove J, Marlais M, Bockenhauer D, Hayes W. Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels. Arch Dis Child. 2023, May;108(5):379\u201384. https:\/\/doi.org\/10.1136\/archdischild-2022-324962. Epub 2023 Jan 30. PMID: 36717209.","journal-title":"Arch Dis Child"},{"key":"4177_CR21","doi-asserted-by":"publisher","unstructured":"Brener R, Zeitlin L, Lebenthal Y, Brener A. Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy. Front Endocrinol (lausanne). 2022, Aug;15(13):947814. https:\/\/doi.org\/10.3389\/fendo.2022.947814. PMID: 36051396; PMCID: PMC9425915.","DOI":"10.3389\/fendo.2022.947814"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04177-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04177-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04177-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:17:03Z","timestamp":1781626623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-025-04177-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4177"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04177-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6385587\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by Tel Aviv Sourasky Medical Center (TLV-0041-19). Written informed consent to participate in this study was provided by the participants\u2019 legal guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent for publication was obtained from the parents of all three patients included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest. Authors RR, AB, YL, and LZ receive speaker fees, research funding, and travel grants from Medison Pharma. Authors RR and YL received advisory board compensation from Medison Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"40"}}